Dechra Pharmaceuticals Management
Management criteria checks 4/4
Dechra Pharmaceuticals' CEO is Ian Page, appointed in Nov 2001, has a tenure of 22.17 years. total yearly compensation is £1.04M, comprised of 59.9% salary and 40.1% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth £15.64M. The average tenure of the management team and the board of directors is 4.8 years and 4.3 years respectively.
Key information
Ian Page
Chief executive officer
UK£1.0m
Total compensation
| CEO salary percentage | 59.9% |
| CEO tenure | 22.2yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31
A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Did You Participate In Any Of Dechra Pharmaceuticals' (LON:DPH) Fantastic 268% Return ?
Jan 18Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Jan 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | UK£1m | UK£621k | -UK£28m |
| Mar 31 2023 | n/a | n/a | UK£6m |
| Dec 31 2022 | n/a | n/a | UK£40m |
| Sep 30 2022 | n/a | n/a | UK£49m |
| Jun 30 2022 | UK£2m | UK£597k | UK£58m |
| Mar 31 2022 | n/a | n/a | UK£66m |
| Dec 31 2021 | n/a | n/a | UK£73m |
| Sep 30 2021 | n/a | n/a | UK£64m |
| Jun 30 2021 | UK£3m | UK£551k | UK£56m |
| Mar 31 2021 | n/a | n/a | UK£50m |
| Dec 31 2020 | n/a | n/a | UK£44m |
| Sep 30 2020 | n/a | n/a | UK£39m |
| Jun 30 2020 | UK£2m | UK£517k | UK£34m |
| Mar 31 2020 | n/a | n/a | UK£31m |
| Dec 31 2019 | n/a | n/a | UK£29m |
| Sep 30 2019 | n/a | n/a | UK£30m |
| Jun 30 2019 | UK£3m | UK£500k | UK£31m |
| Mar 31 2019 | n/a | n/a | UK£28m |
| Dec 31 2018 | n/a | n/a | UK£25m |
| Sep 30 2018 | n/a | n/a | UK£30m |
| Jun 30 2018 | UK£3m | UK£500k | UK£36m |
| Mar 31 2018 | n/a | n/a | UK£40m |
| Dec 31 2017 | n/a | n/a | UK£43m |
| Sep 30 2017 | n/a | n/a | UK£35m |
| Jun 30 2017 | UK£3m | UK£490k | UK£26m |
Compensation vs Market: Ian's total compensation ($USD1.31M) is below average for companies of similar size in the UK market ($USD3.18M).
Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.
CEO
Ian Page (62 yo)
22.2yrs
Tenure
UK£1,037,000
Compensation
Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 22.2yrs | UK£1.04m | 0.36% £ 15.6m | |
| CFO & Executive Director | 4.8yrs | UK£641.00k | 0.010% £ 452.7k | |
| Chief Scientific Officer | 1.5yrs | no data | no data | |
| Chief Information Officer | 1.6yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| President of North America | no data | no data | no data | |
| Company Secretary | 6.5yrs | no data | no data |
4.8yrs
Average Tenure
53yo
Average Age
Experienced Management: DPH's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 26.6yrs | UK£1.04m | 0.36% £ 15.6m | |
| CFO & Executive Director | 4.3yrs | UK£641.00k | 0.010% £ 452.7k | |
| Independent Non-Executive Director | less than a year | UK£36.00k | no data | |
| Senior Independent Director | 7.1yrs | UK£107.00k | 0.0052% £ 227.2k | |
| Independent Non-Executive Chairman | 3.8yrs | UK£207.00k | 0.0033% £ 143.6k | |
| Designated Non-Executive Director | 4.9yrs | UK£72.00k | 0.0012% £ 53.3k | |
| Independent Non-Executive Director | 1.6yrs | UK£73.00k | 0.00053% £ 23.3k |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Board: DPH's board of directors are considered experienced (4.3 years average tenure).